Safety and pharmacokinetics of a single 1500-mg dose of famciclovir in adolescents with recurrent herpes labialis.

Abstract

An open-label study evaluated the safety (n = 53) and pharmacokinetics (n = 8) of single-dose therapy with 1500 mg famciclovir (prodrug of penciclovir) for recurrent herpes labialis in adolescents. Mean Cmax, mean AUC0-∞, and clearance for penciclovir were 9.37 μg/mL, 31.8 μg · h/mL, and 38.2 L/h, respectively, and within the range extrapolated from data in adults. Adverse events were generally mild and transient.

• Authors: Stan L Block, Ram Yogev, Felix Waldmeier, Kamal Hamed
• Journal: The Pediatric infectious disease journal (Pediatr Infect Dis J) Vol. 30 Issue 6 Pg. 525-8 (Jun 2011) ISSN: 1532-0987 [Electronic] United States
• PMID: 21178655 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antiviral Agents
• 2-Aminopurine
• Famciclovir

Topics

• 2-Aminopurine (administration & dosage, adverse effects, analogs & derivatives, pharmacokinetics)
• Adolescent
• Antiviral Agents (administration & dosage, adverse effects, pharmacokinetics)
• Child
• Famciclovir
• Female
• Herpes Labialis (drug therapy)
• Humans
• Male
• Metabolic Clearance Rate
• Recurrence
• Serum (chemistry)